{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T20:55:41Z","timestamp":1789678541164,"version":"4.0.1"},"reference-count":163,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:00:00Z","timestamp":1769126400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Thyroid cancer (TC) is the most common malignant tumor of the endocrine system. Although most cases have a favorable prognosis, some patients may be resistant to treatment or exhibit aggressive behavior. The tumor microenvironment (TME) network, composed of stromal cells, immune cells, vascular cells, and cancer cells, has become a key factor in the development of TC. The TME affects the biological behavior of TC through different immune states. TC cells can suppress antitumor immune response by promoting an immunosuppressive microenvironment, such as through the recruitment of tumor-associated macrophages (TAMs), tumor-associated mast cells (TAMCs), myeloid-derived suppressor cells (MDSCs), tumor-associated neutrophils (TANs), and regulatory T cells (Tregs), among other immunosuppressive cells. They also express negative immune checkpoints such as programmed death ligand 1 (PD-L1) and cytotoxic T lymphocyte-associated protein 4 (CTLA-4), and immunosuppressive enzymes such as indoleamine 2,3-dioxygenase 1 (IDO1). This suggests that immunotherapy may be a promising treatment for TC, especially for patients who do not respond to traditional therapies. This article focuses on the interaction mechanism of cells and molecules in the tumor immune microenvironment (TiME) involved in the occurrence and development of TC and analyzes its potential value as a therapeutic target. In addition, the latest clinical trials related to immunotherapy for TC are summarized.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1699500","type":"journal-article","created":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T06:45:54Z","timestamp":1769150754000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["New insights into the tumor immune microenvironment and immunotherapy of thyroid cancer"],"prefix":"10.3389","volume":"17","author":[{"given":"Jia-jia","family":"Du","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-022-03274-7","article-title":"NCD Research Group, Global Health, Association of Pacific Rim Universities (APRU). Incidence and mortality of thyroid cancer in 50 countries: a joinpoint regression analysis of global trends","volume":"80","author":"Huang","year":"2023","journal-title":"Endocrine."},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.26348","article-title":"Thyroid cancer: A review","volume":"331","author":"Boucai","year":"2024","journal-title":"JAMA."},{"key":"B3","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1007\/s13193-021-01398-2","article-title":"Systemic therapy in thyroid cancer","volume":"13","author":"Agrawal","year":"2022","journal-title":"Indian J Surg Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.04.009","article-title":"Electronic address: clinicalguidelines@esmo.org. ESMO Clinical Practice Guideline update on the use of systemic therapy in advanced thyroid cancer","volume":"33","author":"Filetti","year":"2022","journal-title":"Ann Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.ecl.2021.11.020","article-title":"Anaplastic thyroid cancer: new horizons and challenges","volume":"51","author":"Maniakas","year":"2022","journal-title":"Endocrinol Metab Clin North Am"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3724\/zdxbyxb-2021-0273","article-title":"Immunotherapy for anaplastic thyroid carcinoma: the present and future","volume":"50","author":"Lu","year":"2021","journal-title":"Zhejiang Da Xue Xue Bao Yi Xue Ban."},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.7150\/jca.44506","article-title":"Immune microenvironment of thyroid cancer","volume":"11","author":"Yin","year":"2020","journal-title":"J Cancer."},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232012578","article-title":"Cell component and function of tumor microenvironment in thyroid cancer","volume":"23","author":"Shin","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.637826","article-title":"Immune landscape of thyroid cancers: new insights","volume":"11","author":"Menicali","year":"2021","journal-title":"Front Endocrinol (Lausanne)."},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2019.10485","article-title":"Metabolic reprogramming and its clinical application in thyroid cancer","volume":"18","author":"Wen","year":"2019","journal-title":"Oncol Lett"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.954992","article-title":"Managing the TME to improve the efficacy of cancer therapy","volume":"13","author":"Bilotta","year":"2022","journal-title":"Front Immunol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/s41419-020-03294-z","article-title":"A new risk factor indicator for papillary thyroid cancer based on immune infiltration","volume":"12","author":"Yang","year":"2021","journal-title":"Cell Death Dis"},{"key":"B13","doi-asserted-by":"publisher","first-page":"e1168556","DOI":"10.1080\/2162402X.2016.1168556","article-title":"The immune network in thyroid cancer","volume":"5","author":"Galdiero","year":"2016","journal-title":"Oncoimmunology."},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2012.0560","article-title":"CD3(-)CD16(-)CD56(bright) immunoregulatory NK cells are increased in the tumor microenvironment and inversely correlate with advanced stages in patients with papillary thyroid cancer","author":"Gogali","year":"2013","journal-title":"Thyroid."},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01859","article-title":"Prostaglandin E2 secreted by thyroid cancer cells contributes to immune escape through the suppression of natural killer (NK) cell cytotoxicity and NK cell differentiation","volume":"9","author":"Park","year":"2018","journal-title":"Front Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2018.09.016","article-title":"Dysfunction of natural killer cells mediated by PD-1 and Tim-3 pathway in anaplastic thyroid cancer","volume":"64","author":"Yin","year":"2018","journal-title":"Int Immunopharmacol."},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00816","article-title":"Natural killer cell (NK-92MI)-based therapy for pulmonary metastasis of anaplastic thyroid cancer in a nude mouse model","volume":"8","author":"Zhu","year":"2017","journal-title":"Front Immunol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.imlet.2014.07.005","article-title":"The prevalence and distribution of Th17 and Tc17 cells in patients with thyroid tumor","volume":"162","author":"Jiang","year":"2014","journal-title":"Immunol Lett"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.894919","article-title":"Immune profiling identifies CD8+ T-cell subset signatures as prognostic markers for recurrence in papillary thyroid cancer","volume":"13","author":"Chen","year":"2022","journal-title":"Front Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20184413","article-title":"Immune and inflammatory cells in thyroid cancer microenvironment","volume":"20","author":"Ferrari","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.18632\/aging.102780","article-title":"Immune-related key gene CLDN10 correlates with lymph node metastasis but predicts favorable prognosis in papillary thyroid carcinoma","volume":"12","author":"Xiang","year":"2020","journal-title":"Aging (Albany NY)."},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-014-1222-6","article-title":"Analysis of regulatory T cells frequency in peripheral blood and tumor tissues in papillary thyroid carcinoma with and without Hashimoto\u2019s thyroiditis","volume":"17","author":"Liu","year":"2015","journal-title":"Clin Transl Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1097\/CCO.0000000000000212","article-title":"Targeting the programmed death-1\/programmed death-ligand 1 axis in lymphoma","volume":"27","author":"Cheah","year":"2015","journal-title":"Curr Opin Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(16)30277-7","article-title":"Leveraging the immune system to treat advanced thyroid cancers","volume":"5","author":"French","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-021-03137-y","article-title":"Diagnostic and prognostic value of tumor-infiltrating B cells in lymph node metastases of papillary thyroid carcinoma","volume":"479","author":"Yang","year":"2021","journal-title":"Virchows Arch"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2014.441","article-title":"Mast cells induce epithelial-to-mesenchymal transition and stem cell features in human thyroid cancer cells through an IL-8-Akt-Slug pathway","volume":"34","author":"Visciano","year":"2015","journal-title":"Oncogene."},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pathmechdis-012418-012718","article-title":"Diversity, mechanisms, and significance of macrophage plasticity","volume":"15","author":"Locati","year":"2020","journal-title":"Annu Rev Pathol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0483-y","article-title":"Nature of coexisting thyroid autoimmune disease determines success or failure of tumor immunity in thyroid cancer","volume":"7","author":"Imam","year":"2019","journal-title":"J Immunother Cancer."},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13194821","article-title":"Secreted factors by anaplastic thyroid cancer cells induce tumor-promoting M2-like macrophage polarization through a TIM3-dependent mechanism","volume":"13","author":"Stempin","year":"2021","journal-title":"Cancers (Basel)."},{"key":"B30","doi-asserted-by":"publisher","first-page":"e000638","DOI":"10.1136\/jitc-2020-000638","article-title":"Enhanced lipid biosynthesis in human tumor-induced macrophages contributes to their protumoral characteristics","volume":"8","author":"Rabold","year":"2020","journal-title":"J Immunother Cancer."},{"key":"B31","doi-asserted-by":"publisher","first-page":"e169653","DOI":"10.1172\/JCI169653","article-title":"Anaplastic transformation in thyroid cancer revealed by single-cell transcriptomics","volume":"133","author":"Lu","year":"2023","journal-title":"J Clin Invest."},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-022-03179-5","article-title":"Integrated analysis of novel macrophage related signature in anaplastic thyroid cancer","volume":"78","author":"Luo","year":"2022","journal-title":"Endocrine."},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy123","article-title":"Early evolutionary divergence between papillary and anaplastic thyroid cancers","volume":"29","author":"Capdevila","year":"2018","journal-title":"Ann Oncol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1002\/mc.23268","article-title":"M2-like tumor-associated macrophages-secreted Wnt1 and Wnt3a promotes dedifferentiation and metastasis via activating \u03b2-catenin pathway in thyroid cancer","volume":"60","author":"Lv","year":"2021","journal-title":"Mol Carcinog."},{"key":"B35","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1111\/cas.14752","article-title":"Interleukin 6 regulates the expression of programmed cell death ligand 1 in thyroid cancer","volume":"112","author":"Zhang","year":"2021","journal-title":"Cancer Sci"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1111\/cen.14120","article-title":"Prognostic role of the lymphocyte-to-monocyte ratio for clinical outcomes of patients with progressive radioiodine-refractory differentiated thyroid carcinoma treated by sorafenib","volume":"92","author":"Ahn","year":"2020","journal-title":"Clin Endocrinol (Oxf)."},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2018.0684","article-title":"Low lymphocyte-to-monocyte ratios are associated with poor overall survival in anaplastic thyroid carcinoma patients","volume":"29","author":"Ahn","year":"2019","journal-title":"Thyroid."},{"key":"B38","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41577-019-0210-z","article-title":"Dendritic cells in cancer immunology and immunotherapy","volume":"20","author":"Wculek","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2015.05.009","article-title":"CD1a-positive dendritic cell density predicts disease-free survival in papillary thyroid carcinoma","volume":"211","author":"Hilly","year":"2015","journal-title":"Pathol Res Pract"},{"key":"B40","doi-asserted-by":"publisher","first-page":"e004049","DOI":"10.1136\/jitc-2021-004049","article-title":"TSH-TSHR axis promotes tumor immune evasion","volume":"10","author":"Wu","year":"2022","journal-title":"J Immunother Cancer."},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-19-0074","article-title":"Papillary thyroid carcinoma behavior: clues in the tumor microenvironment","volume":"26","author":"Bergdorf","year":"2019","journal-title":"Endocr Relat Cancer."},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-17-0316","article-title":"Immune responses in the thyroid cancer microenvironment: making immunotherapy a possible mission","volume":"24","author":"Mould","year":"2017","journal-title":"Endocr Relat Cancer."},{"key":"B43","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1172\/JCI130952","article-title":"Relief of tumor hypoxia unleashes the tumoricidal potential of neutrophils","volume":"130","author":"Mahiddine","year":"2020","journal-title":"J Clin Invest."},{"key":"B44","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/j.ccell.2017.11.004","article-title":"Myeloid cell-derived reactive oxygen species induce epithelial mutagenesis","volume":"32","author":"Canli","year":"2017","journal-title":"Cancer Cell"},{"key":"B45","doi-asserted-by":"publisher","first-page":"e0199740","DOI":"10.1371\/journal.pone.0199740","article-title":"Potential involvement of neutrophils in human thyroid cancer","volume":"28","author":"Galdiero","year":"2018","journal-title":"PloS One"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1900543","article-title":"Anaplastic thyroid cancer cells induce the release of mitochondrial extracellular DNA traps by viable neutrophils","volume":"204","author":"Cristinziano","year":"2020","journal-title":"J Immunol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.7150\/ijms.28498","article-title":"An increased neutrophil-to-lymphocyte ratio predicts incomplete response to therapy in differentiated thyroid cancer","volume":"15","author":"Lee","year":"2018","journal-title":"Int J Med Sci"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3892\/mco.2013.170","article-title":"Immunosuppression involving increased myeloid-derived suppressor cell levels, systemic inflammation and hypoalbuminemia are present in patients with anaplastic thyroid cancer","volume":"1","author":"Suzuki","year":"2013","journal-title":"Mol Clin Oncol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-022-03008-9","article-title":"Prolonged survival of anaplastic thyroid carcinoma is associated with resectability, low tumor-infiltrating neutrophils\/myeloid-derived suppressor cells, and low peripheral neutrophil-to-lymphocyte ratio","volume":"76","author":"Xu","year":"2022","journal-title":"Endocrine."},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa344","article-title":"Circulating myeloid-derived suppressor cells facilitate invasion of thyroid cancer cells by repressing miR-486-3p","volume":"105","author":"Chen","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1038\/s41467-022-29000-5","article-title":"Targeting myeloid derived suppressor cells reverts immune suppression and sensitizes BRAF-mutant papillary thyroid cancer to MAPK inhibitors","volume":"13","author":"Zhang","year":"2022","journal-title":"Nat Commun"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-020-0539-7","article-title":"Papillary thyroid carcinoma with prominent myofibroblastic stromal component: clinicopathologic, immunohistochemical and next-generation sequencing study of seven cases","volume":"33","author":"Suster","year":"2020","journal-title":"Mod Pathol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"8028","DOI":"10.1038\/s41598-019-44361-6","article-title":"Interplay of fibroblasts with anaplastic tumor cells promotes follicular thyroid cancer progression","volume":"9","author":"Fozzatti","year":"2019","journal-title":"Sci Rep"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-020-01391-1","article-title":"Papillary thyroid cancer-aggressive variants and impact on management: A narrative review","volume":"37","author":"Coca-Pelaz","year":"2020","journal-title":"Adv Ther"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14174172","article-title":"Thyroid cancer and fibroblasts","volume":"14","author":"Avagliano","year":"2022","journal-title":"Cancers (Basel)."},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S294725","article-title":"Cancer-associated fibroblasts positively correlate with dedifferentiation and aggressiveness of thyroid cancer","volume":"14","author":"Wen","year":"2021","journal-title":"Onco Targets Ther"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.3390\/cells11193181","article-title":"MEG3 expression indicates lymph node metastasis and presence of cancer-associated fibroblasts in papillary thyroid cancer","volume":"11","author":"Dadafarin","year":"2022","journal-title":"Cells."},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-01167","article-title":"Immune profiling of thyroid carcinomas suggests the existence of two major phenotypes: an ATC-like and a PDTC-like","volume":"104","author":"Giannini","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20061405","article-title":"PD-1 ligand expression in epithelial thyroid cancers: potential clinical implications","volume":"20","author":"Ulisse","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B60","doi-asserted-by":"publisher","first-page":"553","DOI":"10.3892\/ol.2021.12814","article-title":"PD-L1 expression and immune cells in anaplastic carcinoma and poorly differentiated carcinoma of the human thyroid gland: A retrospective study","volume":"22","author":"Cameselle-Garc\u00eda","year":"2021","journal-title":"Oncol Lett"},{"key":"B61","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s12022-018-9514-y","article-title":"PD-L1 and IDO1 are expressed in poorly differentiated thyroid carcinoma","volume":"29","author":"Rosenbaum","year":"2018","journal-title":"Endocr Pathol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-018-2357-6","article-title":"In papillary thyroid carcinoma, expression by immunohistochemistry of BRAF V600E, PD-L1, and PD-1 is closely related","volume":"472","author":"Bai","year":"2018","journal-title":"Virchows Arch"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1084\/jem.182.2.459","article-title":"CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation","volume":"182","author":"Krummel","year":"1995","journal-title":"J Exp Med"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1438235","article-title":"Immune microenvironment in papillary thyroid carcinoma: roles of immune cells and checkpoints in disease progression and therapeutic implications","volume":"15","author":"Zheng","year":"2024","journal-title":"Front Immunol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1007\/s12022-024-09832-1","article-title":"Unravelling the reasons behind limited response to anti-PD therapy in ATC: A comprehensive evaluation of tumor-infiltrating immune cells and checkpoints","volume":"35","author":"Boruah","year":"2024","journal-title":"Endocr Pathol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"e005538","DOI":"10.1136\/jitc-2022-005538","article-title":"Preconditioning of the immune system modulates the response of papillary thyroid cancer to immune checkpoint inhibitors","volume":"10","author":"Pani","year":"2022","journal-title":"J Immunother Cancer."},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa701","article-title":"Immune co-inhibitory receptors PD-1, CTLA-4, TIM-3, LAG-3, and TIGIT in medullary thyroid cancers: A large cohort study","volume":"106","author":"Shi","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"B68","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1016\/j.humpath.2007.11.015","article-title":"Nuclear factor-kappaB activation is associated with somatic and germ line RET mutations in medullary thyroid carcinoma","volume":"39","author":"Gallel","year":"2008","journal-title":"Hum Pathol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2019.0604","article-title":"Comprehensive immune profiling of medullary thyroid cancer","volume":"30","author":"Pozdeyev","year":"2020","journal-title":"Thyroid."},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241210019","article-title":"CD276 as a candidate target for immunotherapy in medullary thyroid cancer","volume":"24","author":"Hi\u0144cza-Nowak","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01124","article-title":"Interleukins in thyroid cancer: from basic researches to applications in clinical practice","volume":"12","author":"Xi","year":"2020","journal-title":"Front Immunol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.14934","article-title":"Propiece IL-1\u03b1 facilitates the growth of acute T-lymphocytic leukemia cells through the activation of NF-\u03baB and SP1","volume":"8","author":"Zhang","year":"2017","journal-title":"Oncotarget."},{"key":"B73","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/labinvest.2015.126","article-title":"IL-12 immunotherapy of Braf(V600E)-induced papillary thyroid cancer in a mouse model","volume":"96","author":"Parhar","year":"2016","journal-title":"Lab Invest."},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-016-1924-4","article-title":"Interleukin 10 expression is related to aggressiveness and poor prognosis of patients with thyroid cancer","volume":"66","author":"Cunha","year":"2017","journal-title":"Cancer Immunol Immunother."},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.7150\/jca.52171","article-title":"ANXA1 enhances tumor proliferation and migration by regulating epithelial-mesenchymal transition and IL-6\/JAK2\/STAT3 pathway in papillary thyroid carcinoma","volume":"12","author":"Zhao","year":"2021","journal-title":"J Cancer."},{"key":"B76","doi-asserted-by":"publisher","first-page":"e23335","DOI":"10.1002\/jcla.23335","article-title":"IL-34 is a potential biomarker for the treatment of papillary thyroid cancer","volume":"34","author":"Zhang","year":"2020","journal-title":"J Clin Lab Anal"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-3045","article-title":"Metformin reverts the secretion of CXCL8 induced by TNF-\u03b1 in primary cultures of human thyroid cells: an additional indirect anti-tumor effect of the drug","volume":"100","author":"Rotondi","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1080\/13102818.2014.909151","article-title":"VEGF expression, microvessel density and dendritic cell decrease in thyroid cancer","volume":"28","author":"Gulubova","year":"2014","journal-title":"Biotechnol Biotechnol Equip."},{"key":"B79","article-title":"Perinatalis v\u00e9r-\u00f3lomszint fokozott \u00f3lomexpoz\u00edci\u00f3j\u00fa v\u00e1rosban [Prenatal lead blood levels in a city heavily exposed to lead","volume":"130","author":"T\u00f3th","year":"1989","journal-title":"Orv Hetil."},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2010.348","article-title":"Mast cells have a protumorigenic role in human thyroid cancer","volume":"29","author":"Melillo","year":"2010","journal-title":"Oncogene."},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2016.5153","article-title":"Promotion of metastasis of thyroid cancer cells via NRP-2-mediated induction","volume":"12","author":"Tu","year":"2016","journal-title":"Oncol Lett"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1210\/er.2007-0007","article-title":"BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications","volume":"28","author":"Xing","year":"2007","journal-title":"Endocr Rev"},{"key":"B83","article-title":"Immunotherapy in anaplastic thyroid cancer","volume":"12","author":"Ma","year":"2020","journal-title":"Am J Transl Res"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2013.0423","article-title":"Expression of indoleamine 2,3-dioxygenase and infiltration of FOXP3+ regulatory T cells are associated with aggressive features of papillary thyroid microcarcinoma","volume":"24","author":"Ryu","year":"2014","journal-title":"Thyroid."},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8060842","article-title":"Indoleamine-2,3-dioxygenase in thyroid cancer cells suppresses natural killer cell function by inhibiting NKG2D and NKp46 expression via STAT signaling pathways","volume":"8","author":"Park","year":"2019","journal-title":"J Clin Med"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00938","article-title":"Myeloid cell-derived arginase in cancer immune response","volume":"11","author":"Grzywa","year":"2020","journal-title":"Front Immunol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1007\/s12022-017-9495-2","article-title":"Immune escape mechanism is impaired in the microenvironment of thyroid lymph node metastasis","volume":"28","author":"Cunha","year":"2017","journal-title":"Endocr Pathol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1111\/cen.12586","article-title":"CD8+ tumour-infiltrating lymphocytes and COX2 expression may predict relapse in differentiated thyroid cancer","volume":"83","author":"Cunha","year":"2015","journal-title":"Clin Endocrinol (Oxf)."},{"key":"B89","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/s41419-022-04817-6","article-title":"METTL3-mediated m6A modification of STEAP2 mRNA inhibits papillary thyroid cancer progress by blocking the Hedgehog signaling pathway and epithelial-to-mesenchymal transition","volume":"13","author":"Zhu","year":"2022","journal-title":"Cell Death Dis"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab480","article-title":"METTL3-induced miR-222-3p upregulation inhibits STK4 and promotes the Malignant behaviors of thyroid carcinoma cells","volume":"107","author":"Lin","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.3390\/metabo12121214","article-title":"Reprogramming of cellular metabolism and its therapeutic applications in thyroid cancer","volume":"12","author":"Nagayama","year":"2022","journal-title":"Metabolites."},{"key":"B92","doi-asserted-by":"publisher","first-page":"C7","DOI":"10.1530\/ERC-11-0360","article-title":"Oxidative stress: a new risk factor for thyroid cancer","volume":"19","author":"Xing","year":"2012","journal-title":"Endocr Relat Cancer"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-023-02294-y","article-title":"Targeting glutamine metabolism exhibits anti-tumor effects in thyroid cancer","volume":"47","author":"Zhang","year":"2024","journal-title":"J Endocrinol Invest."},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1530\/EC-21-0135","article-title":"SHMT2 expression as a diagnostic and prognostic marker for thyroid cancer","volume":"10","author":"Jin","year":"2021","journal-title":"Endocr Connect."},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2020.5158","article-title":"Serine, glycine and one\u2212carbon metabolism in cancer (Review)","volume":"58","author":"Pan","year":"2021","journal-title":"Int J Oncol"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/8678363","article-title":"Cystathionine \u03b2-synthase regulates the proliferation, migration, and invasion of thyroid carcinoma cells","volume":"2022","author":"Jiang","year":"2022","journal-title":"Oxid Med Cell Longev"},{"key":"B97","doi-asserted-by":"publisher","first-page":"e1229725","DOI":"10.1080\/2162402X.2016.1229725","article-title":"Transcriptional and metabolic reprogramming induce an inflammatory phenotype in non-medullary thyroid carcinoma-induced macrophages","volume":"9","author":"Arts","year":"2016","journal-title":"Oncoimmunology."},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1677\/ERC-08-0036","article-title":"Increased density of tumor-associated macrophages is associated with decreased survival in advanced thyroid cancer","volume":"15","author":"Ryder","year":"2008","journal-title":"Endocr Relat Cancer."},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1038\/ni.3269","article-title":"Glycolysis controls the induction of human regulatory T cells by modulating the expression of FOXP3 exon 2 splicing variants","volume":"16","author":"De Rosa","year":"2015","journal-title":"Nat Immunol"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1016\/j.surg.2021.05.055","article-title":"Glycolytic inhibition with 3-bromopyruvate suppresses tumor growth and improves survival in a murine model of anaplastic thyroid cancer","volume":"171","author":"Zhao","year":"2022","journal-title":"Surgery."},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.3390\/biom12040574","article-title":"Metformin in differentiated thyroid cancer: molecular pathways and its clinical implications","volume":"14","author":"Garc\u00eda-S\u00e1enz","year":"2022","journal-title":"Biomolecules."},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.2000137","article-title":"Metformin and 2-deoxyglucose collaboratively suppress human CD4+ T cell effector functions and activation-induced metabolic reprogramming","volume":"205","author":"Tan","year":"2020","journal-title":"J Immunol"},{"key":"B103","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1038\/s41419-021-04081-0","article-title":"STAT3\/LINC00671 axis regulates papillary thyroid tumor growth and metastasis via LDHA-mediated glycolysis","volume":"17","author":"Huo","year":"2021","journal-title":"Cell Death Dis"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.16453","article-title":"HYOU1 facilitates proliferation, invasion and glycolysis of papillary thyroid cancer via stabilizing LDHB mRNA","volume":"25","author":"Wang","year":"2021","journal-title":"J Cell Mol Med"},{"key":"B105","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1530\/ERC-21-0153","article-title":"Reduced MHC class II expression in medullary thyroid cancer identifies patients with poor prognosis","volume":"29","author":"Ruan","year":"2022","journal-title":"Endocr Relat Cancer."},{"key":"B106","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s40880-018-0301-4","article-title":"Lipid metabolism reprogramming and its potential targets in cancer","volume":"21","author":"Cheng","year":"2018","journal-title":"Cancer Commun (Lond)."},{"key":"B107","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/s41416-019-0650-z","article-title":"Reprogramming of fatty acid metabolism in cancer","volume":"122","author":"Koundouros","year":"2020","journal-title":"Br J Cancer."},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2019.04.006","article-title":"Dietary cholesterol is essential to mast cell activation and associated obesity and diabetes in mice","volume":"1865","author":"Zhang","year":"2019","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.3906\/sag-1708-106","article-title":"Thyroid volumes and serum VEGF levels in dyslipidemic patients: effects of statin treatment","volume":"49","author":"Ayd\u0131n","year":"2019","journal-title":"Turk J Med Sci"},{"key":"B110","doi-asserted-by":"publisher","first-page":"e005940","DOI":"10.1136\/jitc-2022-005940","article-title":"Statin drugs enhance responses to immune checkpoint blockade in head and neck cancer models","volume":"11","author":"Kansal","year":"2023","journal-title":"J Immunother Cancer."},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1111\/bph.15277","article-title":"Identification and characterization of a novel adiponectin receptor agonist adipo anti-inflammation agonist and its anti-inflammatory effects in vitro and in vivo","volume":"178","author":"Qiu","year":"2021","journal-title":"Br J Pharmacol"},{"key":"B112","first-page":"3992","article-title":"Effect of IL-6 on proliferation of human thyroid anaplastic cancer stem cells","volume":"12","author":"Zheng","year":"2019","journal-title":"Int J Clin Exp Pathol"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19030730","article-title":"The balance of th17 versus treg cells in autoimmunity","volume":"3","author":"Lee","year":"2018","journal-title":"Int J Mol Sci"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.7150\/jca.63545","article-title":"APOE is a prognostic biomarker and correlates with immune infiltrates in papillary thyroid carcinoma","volume":"13","author":"Lin","year":"2022","journal-title":"J Cancer."},{"key":"B115","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s13046-022-02254-z","article-title":"FTO suppresses glycolysis and growth of papillary thyroid cancer via decreasing stability of APOE mRNA in an N6-methyladenosine-dependent manner","volume":"28","author":"Huang","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.12.014","article-title":"Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study","volume":"33","author":"Subbiah","year":"2022","journal-title":"Ann Oncol"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-17-0532","article-title":"Immune landscape of papillary thyroid cancer and immunotherapeutic implications","volume":"25","author":"Na","year":"2018","journal-title":"Endocr Relat Cancer."},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2014.0134","article-title":"BRAF V600E in papillary thyroid carcinoma is associated with increased programmed death ligand 1 expression and suppressive immune cell infiltration","volume":"24","author":"Angell","year":"2014","journal-title":"Thyroid."},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-4227","article-title":"Tumor-infiltrating T cells and the PD-1 checkpoint pathway in advanced differentiated and anaplastic thyroid cancer","volume":"101","author":"Bastman","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1002\/hed.25740","article-title":"Tumor immune microenvironment characteristics of papillary thyroid carcinoma are associated with histopathological aggressiveness and BRAF mutation status","volume":"41","author":"Means","year":"2019","journal-title":"Head Neck."},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2018.03.023","article-title":"The immune landscape of cancer","volume":"48","author":"Thorsson","year":"2018","journal-title":"Immunity."},{"key":"B122","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/s41573-018-0007-y","article-title":"Approaches to treat immune hot, altered and cold tumours with combination immunotherapies","volume":"18","author":"Galon","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.32604\/or.2023.029924","article-title":"Tumor neoantigens: Novel strategies for application of cancer immunotherapy","volume":"31","author":"Guan","year":"2023","journal-title":"Oncol Res"},{"key":"B124","doi-asserted-by":"publisher","first-page":"e007097","DOI":"10.1136\/jitc-2023-007097","article-title":"Identification of neoepitope reactive T-cell receptors guided by HLA-A*03:01 and HLA-A*11:01 immunopeptidomics","volume":"11","author":"Ade","year":"2023","journal-title":"J Immunother Cancer."},{"key":"B125","doi-asserted-by":"publisher","first-page":"2764","DOI":"10.1038\/s41467-019-10680-5","article-title":"Integrative analysis of genomic and transcriptomic characteristics associated with progression of aggressive thyroid cancer","volume":"10","author":"Yoo","year":"2019","journal-title":"Nat Commun"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1172\/JCI85271","article-title":"Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers","volume":"126","author":"Landa","year":"2016","journal-title":"J Clin Invest."},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.00490","article-title":"A case report of sequential use of a yeast-CEA therapeutic cancer vaccine and anti-PD-L1 inhibitor in metastatic medullary thyroid cancer","volume":"11","author":"Del Rivero","year":"2020","journal-title":"Front Endocrinol (Lausanne)."},{"key":"B128","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1186\/s12885-018-4522-3","article-title":"Recombinant oncolytic Newcastle disease virus displays antitumor activities in anaplastic thyroid cancer cells","volume":"18","author":"Jiang","year":"2018","journal-title":"BMC Cancer."},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2006.0178","article-title":"Results of a phase I clinical study using dendritic cell vaccinations for thyroid cancer","volume":"17","author":"Kuwabara","year":"2007","journal-title":"Thyroid."},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1177\/030089161109700420","article-title":"Expression and correlation of sodium\/iodide symporter and thyroid stimulating hormone receptor in human thyroid carcinoma","volume":"97","author":"Wang","year":"2011","journal-title":"Tumori."},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab819","article-title":"and potent preclinical activity against differentiated thyroid cancer","volume":"107","author":"Li","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"B132","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s40164-022-00311-z","article-title":"Chimeric antigen receptor T-cell therapy for relapsed and refractory thyroid cancer","volume":"11","author":"Ding","year":"2022","journal-title":"Exp Hematol Oncol"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1016\/j.omto.2021.01.012","article-title":"Adoptive T cell immunotherapy for medullary thyroid carcinoma targeting GDNF family receptor alpha 4","volume":"20","author":"Bhoj","year":"2021","journal-title":"Mol Ther Oncolytics."},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2022.0020","article-title":"T cells engineered to express immunoreceptors targeting the frequently expressed medullary thyroid cancer antigens calcitonin, CEA, and RET M918T","volume":"32","author":"Erickson","year":"2022","journal-title":"Thyroid."},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1052672","article-title":"Roles of intercellular cell adhesion molecule-1 (ICAM-1) in colorectal cancer: expression, functions, prognosis, tumorigenesis, polymorphisms and therapeutic implications","volume":"12","author":"Qiu","year":"2022","journal-title":"Front Oncol"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-2008","article-title":"CAR T therapy targeting ICAM-1 eliminates advanced human thyroid tumors","volume":"23","author":"Min","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.6112","article-title":"Safety and efficacy of AIC100 chimeric antigen receptor (CAR) T-cell therapy in patients with advanced thyroid cancers: Results from the phase 1 study","volume":"42","author":"Srour","year":"2024","journal-title":"JCO"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.7150\/jca.30163","article-title":"An antibody fab fragment-based chimeric antigen receptor could efficiently eliminate human thyroid cancer cells","volume":"10","author":"Duan","year":"2019","journal-title":"J Cancer."},{"key":"B139","article-title":"Targeting TGF-\u03b21 suppresses survival of and invasion by anaplastic thyroid carcinoma cells","volume":"9","author":"Sun","year":"2017","journal-title":"Am J Transl Res"},{"key":"B140","article-title":"Targeting TGF-\u03b21 inhibits invasion of anaplastic thyroid carcinoma cell through SMAD2-dependent S100A4-MMP-2\/9 signalling","volume":"8","author":"Zhang","year":"2016","journal-title":"Am J Transl Res"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13030418","article-title":"Targeting the sonic hedgehog pathway to suppress the expression of the cancer stem cell (CSC)-related transcription factors and CSC-driven thyroid tumor growth","volume":"13","author":"Lu","year":"2021","journal-title":"Cancers (Basel)."},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-13-0187","article-title":"Off-target effects of c-MET inhibitors on thyroid cancer cells","volume":"13","author":"Zhou","year":"2014","journal-title":"Mol Cancer Ther"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1139\/bcb-2017-0074","article-title":"The CXCL12-CXCR4 axis promotes migration, invasiveness, and EMT in human papillary thyroid carcinoma B-CPAP cells via NF-\u03baB signaling","volume":"96","author":"Lin","year":"2018","journal-title":"Biochem Cell Biol"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1016\/j.surg.2015.10.016","article-title":"Integrin-linked kinase affects signaling pathways and migration in thyroid cancer cells and is a potential therapeutic target","volume":"159","author":"Shirley","year":"2016","journal-title":"Surgery."},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14174160","article-title":"Tumor infiltrating lymphocyte (TIL) therapy for solid tumor treatment: progressions and challenges","volume":"14","author":"Zhao","year":"2022","journal-title":"Cancers (Basel)."},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34657","article-title":"Efficacy and safety of pembrolizumab monotherapy in patients with advanced thyroid cancer in the phase 2 KEYNOTE-158 study","volume":"129","author":"Oh","year":"2023","journal-title":"Cancer."},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02727","article-title":"PD-1 blockade in anaplastic thyroid carcinoma","volume":"38","author":"Capdevila","year":"2020","journal-title":"J Clin Oncol"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2022.0073","article-title":"An evaluation of clinical efficacy of immune checkpoint inhibitors for patients with anaplastic thyroid carcinoma","volume":"32","author":"Hatashima","year":"2022","journal-title":"Thyroid."},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.6082","article-title":"Benefits of pembrolizumab in progressive radioactive iodine refractory thyroid cancer: Results of the AcS\u00e9 Pembrolizumab Study from Unicancer","volume":"39","author":"Leboulleux","year":"2021","journal-title":"JCO"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.6024","article-title":"Phase I\/II study of spartalizumab (PDR001), an anti-PD1 mAb, in patients with anaplastic thyroid cancer","volume":"36","author":"Wirth","year":"2018","journal-title":"JCO"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.6513","article-title":"A phase II study of nivolumab (N) plus ipilimumab (I) in radioidine refractory differentiated thyroid cancer (RAIR DTC) with exploratory cohorts in anaplastic (ATC) and medullary thyroid cancer (MTC)","volume":"38","author":"Lorch","year":"2020","journal-title":"JCO."},{"key":"B152","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s40425-018-0378-y","article-title":"Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma","volume":"6","author":"Iyer","year":"2018","journal-title":"J Immunother Cancer."},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2020.0322","article-title":"Combination of lenvatinib and pembrolizumab is an effective treatment option for anaplastic and poorly differentiated thyroid carcinoma","volume":"31","author":"Dierks","year":"2021","journal-title":"Thyroid."},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.07.1726","article-title":"1646MO phase II ATLEP trial: final results for lenvatinib\/pembrolizumab in metastasized anaplastic and poorly differentiated thyroid carcinoma","volume":"33","author":"Dierks","year":"2022","journal-title":"Ann Oncol"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.6512","article-title":"Lenvatinib plus pembrolizumab combination therapy in patients with radioiodine-refractory (RAIR), progressive differentiated thyroid cancer (DTC): Results of a multicenter phase II international thyroid oncology group trial","volume":"38","author":"Haugen","year":"2020","journal-title":"JCO."},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1177\/0300891621996817","article-title":"Adjuvant radiotherapy and radioiodine treatment for locally advanced differentiated thyroid cancer: systematic review and meta-analysis","volume":"107","author":"Dicuonzo","year":"2021","journal-title":"Tumori."},{"key":"B157","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1089\/thy.2022.0050","article-title":"A pilot study of durvalumab (MEDI4736) with tremelimumab in combination with image-guided stereotactic body radiotherapy in the treatment of metastatic anaplastic thyroid cancer","volume":"32","author":"Lee","year":"2022","journal-title":"Thyroid."},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2019.0086","article-title":"A phase 2 study of pembrolizumab combined with chemoradiotherapy as initial treatment for anaplastic thyroid cancer","volume":"29","author":"Chintakuntlawar","year":"2019","journal-title":"Thyroid."},{"key":"B159","doi-asserted-by":"publisher","first-page":"987","DOI":"10.7150\/thno.17322","article-title":"Obatoclax and LY3009120 efficiently overcome vemurafenib resistance in differentiated thyroid cancer","volume":"7","author":"Wei","year":"2017","journal-title":"Theranostics."},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2020.03.025","article-title":"Molecular mechanisms of resistance to BRAF and MEK inhibitors in BRAFV600E non-small cell lung cancer","volume":"132","author":"Facchinetti","year":"2020","journal-title":"Eur J Cancer."},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.6514","article-title":"Atezolizumab combinations with targeted therapy for anaplastic thyroid carcinoma (ATC)","volume":"38","author":"Cabanillas","year":"2020","journal-title":"JCO"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2019.0133","article-title":"Complete surgical resection following neoadjuvant dabrafenib plus trametinib in BRAFV600E-mutated anaplastic thyroid carcinoma","volume":"29","author":"Wang","year":"2019","journal-title":"Thyroid."},{"key":"B163","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1186\/s12885-019-5380-3","article-title":"Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced, PD-L1-positive papillary or follicular thyroid cancer","volume":"19","author":"Mehnert","year":"2019","journal-title":"BMC Cancer."}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1699500\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T06:45:56Z","timestamp":1769150756000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1699500\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,23]]},"references-count":163,"alternative-id":["10.3389\/fimmu.2026.1699500"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1699500","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,23]]},"article-number":"1699500"}}